Life Edit Therapeutics
SHAORONG (Ron) CHONG is an accomplished scientist with extensive experience in CRISPR technology and protein engineering. Currently serving as Vice President of CRISPR Technology Development at Life Edit Therapeutics since March 2022, Ron previously held significant roles at Arbor Biotechnologies from May 2017 to February 2022, including Discovery Strategy Fellow and Director of Protein Engineering, where efforts focused on high throughput CRISPR discovery. Prior to that, Ron spent over two decades at New England Biolabs as a Senior Principal Scientist, working on protein discovery and engineering platforms. Ron holds a PhD in Natural Products Chemistry and Pharmacognosy from the University of Michigan and a Bachelor's degree in Plant Physiology and Biochemistry from Peking University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.